

QUANTIFYING THE GLOBAL RATES OF NAUSEA AND VOMITING OF PREGNANCY: A META-ANALYSIS

Thomas R Einarson^{1,2}, Charles Piwko³, Gideon Koren^{1,2}

¹Leslie Dan Faculty of Pharmacy, University of Toronto; ²Division of Clinical Pharmacology, Department of Pediatrics, Hospital For Sick Children, Toronto, Canada; ³Pivina Consulting Inc., Mississauga, Canada

Corresponding Author: t.einarson@rogers.com

Symposium Proceedings from "Morning Sickness – A New Morning for American Women"

ABSTRACT

Background

Nausea and vomiting of pregnancy (NVP) is the most common medical condition in pregnancy, affecting women worldwide. It is unclear whether its prevalence and severity NVP are variable across different nations and races.

Purpose

To summarize global rates of NVP as reported in the literature using meta-analysis.

Methods

We searched Medline, Embase and Cochrane databases for all peer-reviewed articles reporting rates of NVP and/or hyperemesis gravidarum (HG). No restrictions were imposed on publication year or language. Numbers of women, studies and NVP rates were extracted and aggregated using a random effects model. Outcomes included: overall rates (i.e., women suffering any nausea or vomiting or both) in early and in late pregnancy, rates of nausea only, symptom severity, and HG rates.

Results

We identified 116 studies, rejecting 37 and accepting 79, of which 59 provided data for NVP (N=93,753 in 13 countries) and 26 for HG (N= 6,155,578). All developed regions of the world were represented (2 studies from Africa, 1 India; none from Latin America). Reported NVP rates varied from 35%-91% (median 69%); the meta-analytic average rate was 69.4% (CI_{95%}:66.5%-72.3%). Among pregnant women, 32.7% had nausea without vomiting and 23.5% overall had NVP continuing into the third trimester. NVP was rated as mild in 40%, moderate in 46% and severe in 14% of cases. The prevalence of HG was 1.1% (CI_{95%}:0.8%-1.3%), with a range of 0.3%-3.6%.

Conclusions

Almost 70% of women worldwide experience NVP, but reported rates vary widely. HG, the most severe form, affects 1.1%.

Key Words: *Nausea, vomiting, pregnancy, epidemiology, prevalence, burden of disease, meta-analysis*

Since the beginning of time, pregnant women have been reported to suffer from a syndrome variously known as morning sickness, pregnancy sickness, or nausea and vomiting of pregnancy (NVP).^{1,2} Reported rates seem to vary widely as does the severity of symptoms. Some symptoms are so severe that women suffer life threatening dehydration and electrolyte imbalance requiring

hospitalization, known as hyperemesis gravidarum (HG).²⁻⁴

All forms of NVP, especially HG, exert a negative impact on the quality of life of affected women.⁵⁻⁸ As well, it impacts healthcare resources and their associated costs.⁸⁻¹⁰ However, little information exists in the literature describing the burden of NVP and HG on healthcare systems. In

order to examine this burden, a precise estimate for the prevalence of each is required. Past reviews have summarized published studies, but none has provided such estimates.

The purpose of this research was therefore to quantitatively summarize reported rates of NVP in the peer-reviewed literature into a precise point estimate, along with a 95% confidence interval. Our objectives were to quantify the incidence of NVP by calculating the overall worldwide rates of a) NVP in early pregnancy and its severity, b) NVP in late pregnancy, c) women suffering from nausea only, and d) HG.

METHODS

Eligible were peer-reviewed articles that presented original research on pregnant women. We accepted papers in any language or published at any time. Posters or presentations at meetings were not accepted, nor were those presented only in abstract form or in books. The unit of analysis was the pregnancy, rather than births, since women could suffer NVP and subsequently experience a termination of that pregnancy; others could have multiple births from one pregnancy. Articles must have presented numbers of pregnant women and numbers who experienced NVP or HG.

For this research, the operational definition of NVP was the syndrome in pregnancy that involves any degree (or duration) of nausea with or without vomiting or retching at any time during pregnancy and which is not associated with other causal factors. HG, described as the most severe form of NVP, has been well recognized for thousands of years;¹ however, a precise definition has yet to be officially agreed upon.^{11,12} Most definitions incorporate a constellation that includes severe persistent or intractable vomiting which occurs in early pregnancy and is not due to other factors.^{11,13-18} Various cutoffs have been used for its timing such as <9 weeks,¹⁴ <16 weeks,¹⁵ and <20 weeks.¹⁶ Not only are symptoms included in the constellation, but also associated outcomes that can be measured objectively including: dehydration,^{14,16} electrolyte imbalance,^{11,13,15-17} weight loss of >5%,^{10,13,15,17,18} and a measure of starvation (ketonuria).^{13,15,16-18} Hospitalization is often included, but is not an absolute requirement.^{11,15,16} We therefore

accepted all papers that claimed to examine HG using any reasonable definition.

Medline, Embase, and Cochrane databases were searched from inception to November 1, 2012. As well, references from retrieved articles were hand searched as were reviews of the subject. Data extracted included author, date, country, number of pregnant women studied, number reporting NVP, and severity of NVP, including HG. Where multiple rates were presented or where there could be overlap (e.g., reporting nausea \pm vomiting and vomiting \pm nausea), only the highest one was used to avoid duplication.

We pooled data for the following outcomes: NVP (i.e., nausea \pm vomiting) in early pregnancy, nausea without vomiting in early pregnancy, NVP in late pregnancy and HG. These rates were aggregated across studies using the meta-analytic method for rates described by Einarson.¹⁹ That method uses inverse variance weighting, giving greater weight to larger studies as well as incorporating between-study variance. The output is the weighted average rate and its standard error, from which 95% confidence intervals can be constructed. Additional descriptive statistics were also calculated for summary rates, such as raw average rate (i.e., sum of NVP cases/ total number of pregnancies), minimum, maximum, and median. As well, when severity of NVP was reported (i.e., as mild, moderate or severe), data were simply aggregated across studies.

RESULTS

The literature search identified 107 potential articles, 39 of which (36%) were rejected for the reasons specified in Table 1.^{5,12,17,18,20-52} Overall, 75 studies were used in this research. There were 72 studies accepted for the main analyses, of which 55 provided data for NVP and 21 for HG (4 studies provided data for both). The 55 NVP studies examined 83,253 women from around the globe. The largest number of studies (n=28; 47%) originated in North America, 21 (36%) from Europe, 5 (8%) from Asia, 3 (5%) from Australasia and 2 (3%) from Africa.

TABLE 1 Rejected Studies (n=37) and Reasons for Rejection

Outcome	Reason for Rejection	First Author (year)
NVP	Patients were recruited based on having NVP (8)	Chou (2006)20, Chou (2008)21, Emelianova (1999)22, Fejzo (2008)23, Kuo (2007)24, Locock (2008)25, Mazzotta (2000)26, Munch (2011)2
	No appropriate data presented (8)	Corey (1992)27, Dickens (1970)28, Markl (2007)29, Markl (2008)30, Pepper (2006)31, Smith (2000)32, Tylden (1968)33, Zhang (1991)34
	Duplicate/overlapping data (4)	Chan (2010)35, Gadsby (1997)12, Klebanoff (1986)36, Weigel (1988)37
	Review (1)	Flaxman (2000)38
Hyperemesis gravidarum	Purposively recruited women with hyperemesis gravidarum in order to study the disease (13)	Bashiri (1995)39, Borgeat (1997)40, Depue (1987)41, Godsey (1991)42, Naef (1995)43, Nageotte (1996)17, Jørgensen (2012)44, Kuru (2012)45, Safari (1998)46, Saha (2011)47, Tan (2010)48, Uguz (2012)49, van Stuijvenberg (1995)50
	Duplicate or overlapping data (3)	Franks (1992)51, Trogstad (2005)18, Vilming (2000)52

TABLE 2 Summary of Published Rates of Nausea and Vomiting in Early Pregnancy

First author (year)	Country	N	Number reporting NVP	Rate
Abraham (1994) ⁵³	Australia	100	62	62.0%
Ananth (1993) ⁵⁴	India	2,500	875	35.0%
Biggs (1975) ⁵⁵	Australia	116	73	62.9%
Boneva (1999) ⁵⁶	USA	4,027	2,854	70.9%
Brandes (1967) ⁵⁷	USA	7,027	5,117	72.8%
Brown (1997) ⁵⁸	USA	549	436	79.4%
Chan (2010) ⁶	Hong Kong	396	360	90.9%
Chan (2011) ⁵⁹	USA	2,407	2,130	88.5%
Chin (1989) ⁶⁰	Hong Kong	1,453	1,092	75.2%
Chou (2003) ⁶¹	USA	113	73	64.6%
Chou (2008) ⁶²	Taiwan	243	188	77.4%
Crystal (1999) ⁶³	USA	129	110	85.3%
Davies (1986) ⁶⁴	UK	212	125	59.0%
Diggory (1962) ⁶⁵	UK	100	88	88.0%
DiIorio (1985) ⁶⁶	USA	78	44	56.4%
Drake (1988) ⁶⁷	Canada	20	13	65.0%
Evans (1986) ⁶⁸	UK	342	284	83.0%
Fairburn (1990) ⁶⁹	UK	50	35	70.0%
Fairburn (1992) ⁷⁰	UK	100	91	91.0%
Fawcett (1986) ⁷¹	USA	70	45	64.3%
Fenster (1991) ⁷²	USA	1,886	1,244	66.0%

Quantifying the global rates of nausea and vomiting of pregnancy: a meta-analysis

First author (year)	Country	N	Number reporting NVP	Rate
Fitzgerald (1984) ⁷³	UK	86	63	73.3%
Gadsby (1993) ⁷⁴	UK	435	292	67.1%
Jahangiri (2011) ⁷⁵	USA	45	26	57.8%
Järnfelt-Samsioe (1983) ⁷⁶	Sweden	911	635	69.7%
Järnfelt-Samsioe (1985) ⁷⁷	Sweden	96	62	64.6%
Jinadu (1990) ⁷⁸	Nigeria	400	266	66.5%
Källén (2003) ⁷⁹	Sweden	3,675	2,906	79.1%
Klebanoff (1985) ⁸⁰	USA	8,007	4,507	56.3%
Kramer (2010) ⁸¹	Canada	551	349	63.3%
Kricker (1986) ⁸²	Australia	429	303	70.6%
Kullander (1976) ⁸³	Sweden	6,578	4,599	69.9%
Lacasse (2009) ⁸	Canada	367	288	78.5%
Lacroix (2000) ⁸⁴	Canada	160	118	73.8%
Lindseth (2005) ⁸⁵	USA	109	76	69.7%
Little (1979) ⁸⁶	USA	210	151	71.9%
Louik (2006) ⁸⁷	USA	22,487	14,998	66.7%
Masson (1985) ⁸⁸	UK	113	65	57.5%
McBride (1991) ⁸⁹	Canada	732	487	66.5%
Medalie (1957) ⁹⁰	Israel	100	71	71.0%
Meyer (1994) ⁹¹	UK	1,513	1,195	79.0%
Milkovich (1976) ⁹²	USA	10,205	6,305	61.8%
Mori (1988) ⁹³	Japan	132	111	84.1%
O'Brien (1995) ⁹⁴	USA	126	81	64.3%
Paarlberg (1996) ⁹⁵	Netherlands	396	181	45.7%
Pettiti (1986) ⁹⁶	USA	1,933	1,318	68.2%
Robertson (1946) ⁹⁷	UK	100	57	57.0%
Semmens (1957) ⁹⁸	USA	2,500	1,091	43.6%
Speert (1954) ⁹⁹	USA	256	165	64.5%
Stewart (1988) ¹⁰⁰	UK	242	167	69.0%
Tierson (1986) ¹⁰¹	USA	414	370	89.4%
Uddenberg (1971) ¹⁰²	Sweden	152	105	69.1%
Velacott (1988) ¹⁰³	UK	500	380	76.0%
Walker (1985) ¹⁰⁴	South Africa	1,771	1,070	60.4%
Weigel (1989) ¹⁰⁵	USA	903	626	69.3%
Werler (1989) ¹⁰⁶	USA	268	182	67.9%
Whitehead (1992) ¹⁰⁷	UK	984	827	84.0%
Wolkind (1978) ¹⁰⁸	UK	96	51	53.1%
Yerushalmy (1965) ¹⁰⁹	USA	3,853	2,740	71.1%

First author (year)	Country	N	Number reporting NVP	Rate
Total		93,753	62,623	66.8%
		Meta-analytic average rate		69.4%
		Standard error		1.5%
		Minimum		35.0%
		Maximum		91.0%
		Median		69%

NVP = nausea and/or vomiting of pregnancy

Table 2 summarizes published rates of nausea and vomiting in early pregnancy.^{6,8,53-109} The meta-analytic summary rate of NVP was 69.4% (CI_{95%}:66.5%-72.3%). That rate includes all women who suffered from any form of NVP, from mild nausea only to both severe nausea, vomiting and retching. Rates ranged from 35% to 91%, with a median of 69% (see Table 2). There was no correlation between sample size and NVP rate ($r = -0.094$, $P = 0.497$); neither sample size ($r = 0.028$, $P = 0.839$) nor NVP rate was related to publication year ($r = 0.135$, $P = 0.332$).

On the other hand, there were some geographical differences noted. The average of the rates reported from most of the developed countries fell within 5% of the meta-analytic average. That included Australia, Canada, Israel, Sweden, UK and USA. However, the countries in East Asia (i.e., Hong Kong, Taiwan and Japan) reported much higher rates ranging from 75% to 91%. Two countries reporting exceptionally low rates were India (35%) and Netherlands (46%).

Reasons for any of these discrepancies could not be determined. There were 10 studies of 11,155 women who reported rates of nausea only (i.e., without vomiting), that appear in Table 3.^{6,59,60,63,73,74,88,93,98} The meta-analytic average rate was 32.7% (CI_{95%}: 21.7%-43.7%). Six studies involving 1342 women presented results according to the severity of the symptoms, categorizing them as either mild, moderate, or severe^{6,8,62,63,81,97} (See Table 4). Overall, the majority (60%) of the women rated their NVP as either moderate or severe, which indicates a serious health burden. Table 5 lists the studies that provided data from 2512 women describing NVP in late pregnancy.^{75,81,85,91,100,108} The weighted average was 23.5% (CI_{95%}: 12.8%-34.2%). Finally, 25 studies

provided rates of HG for more than 6.1 million women. They are summarized in Table 6.^{2,3,53,55,60,80,98,110-127}

DISCUSSION

Perhaps the most comprehensive previous review was that by Gadsby and Barrie-Adshead, which is available online.¹²⁸ Those authors reviewed 26 articles on NVP involving 39,710 women and 18 articles that examined 13,489 with HG, but did not pool results into point estimates. The present analysis retrieved 59 studies of NVP with 93,753 women and 25 studies of HG with more than 6.1 million. Thus, we have added to the literature and provided precise estimates for these outcomes.

Rates on NVP varied widely, from 35% to 91%, with higher rates reported in East Asian countries. Some variations could reflect bias due to sampling, timing of data collection, or methods of data collection. On the other and, they could be reflecting real differences due to genetics, ethnic or cultural differences, healthcare systems (or lack thereof). In order to address such differences, we did use random effects which does account, at least in part, for some of the differences among studies. Therefore, depending on the focus of future research, it might be advisable to use country specific values. It is noteworthy that few studies were produced in the least developed areas of the world. Aside from a single paper from India, there has been nothing from south or south-east Asia. No studies described rates of NVP in South America, and there were only two from Africa and one from India, thus precluding the majority of women worldwide, and concentrating on the have's rather on the have-nots. This lack of research in developing countries is most bothersome, as women in these regions have

many other risk factors for adverse pregnancy outcome.

In examining the literature on this topic, we became aware of a lack of standard definitions for many terms used in researching this topic. Neither NVP nor HG has a standard definition that is universally accepted. Official organizations need to generate suitable definitions and that such definitions should be used in the future. As well, different authors have defined early and late pregnancy in a variety of ways. Furthermore, standard (precise) definitions are needed for the descriptors mild, moderate and severe.

Not only do definitions vary, but also presentation of results. The ideal would be to present results using all four categories: no NVP, mild, moderate, severe. However, authors often combined categories such as none/mild or mild/moderate or moderate/severe. Such categorizations tend to create more confusion than clarity and prevent the combination of results.

Only a few studies have examined the impact of NVP on resource utilization and costs. The only paper to address NVP in general as well as HG was a Canadian study done by Piwko and coworkers in 2005.¹⁰ However, they calculated only weekly costs and not the overall cost per patient, so projections to the population are difficult. HG has been examined in three additional papers. In the USA, Attard and colleagues⁹ found quite similar results to those of Piwko.¹⁰ Bailit and colleagues

estimated that the total burden of HG in California during 1999 was \$200 million.¹¹³ Similarly, Gadsby and Barnie-Adshead calculated that HG cost the National Health Service of England £36.5 million during 2003/2004.¹²⁸ Little else has been done for a condition that is so widespread.

In observational studies, several authors have noted that appropriate treatment for NVP, especially preventive, is associated with a decrease in the severity of symptoms.^{8,129-131} A randomized controlled trial of doxylamine plus vitamin B6 Diclectin® has confirmed these observations.¹³² Therefore, more research is needed in this area, as very little is presently known about this relatively common medical problem.

CONCLUSIONS

Precise rates of NVP and HG have been calculated. NVP affects about 70% of all women and appears to exert a huge burden on healthcare budgets. However, rates in most developing countries are not available. Its impact requires further investigation, especially in poor countries where women face many other risk factors for poor pregnancy outcome. HG affects about 1.1% of pregnant women and has severe consequences, but its impact on resources and costs has seldom been addressed. More research is needed due the widespread nature of these problems

TABLE 3 Reported Rates of Women Having Only Nausea in Early Pregnancy

First author (year)	Country	N*	Number reporting nausea only	Rate
Chan (2010) ⁶	Hong Kong	396	136	34.3%
Chan (2011) ⁵⁹	USA	2,405	849	35.3%
Chin (2008) ⁶⁰	Hong Kong	1,453	165	11.4%
Crystal (1999) ⁶³	USA	129	58	45.0%
Fitzgerald (1984) ⁷³	UK	86	39	45.3%
Gadsby (1993) ⁷⁴	UK	266	75	28.2%
Källén (2003) ⁷⁹	Sweden	3,675	1,443	39.3%
Masson (1985) ⁸⁸	UK	113	37	32.7%
Mori (1988) ⁹³	Japan	132	69	52.3%
Semmens (1957) ⁹⁸	USA	2,500	155	6.2%
Total		11,155	3,026	27.1%

Meta-analytic average rate	32.7%
Standard error	5.6%
Minimum	6.2%
Maximum	52.3%
Median	35%

TABLE 4 Reported Severity of Nausea and Vomiting in Early Pregnancy*

Author	N	mild	%	moderate	%	severe	%
Chan (2010) ⁶	360	149	41%	205	57%	6	2%
Chou (2008) ⁶²	188	70	37%	88	47%	30	16%
Crystal (1999) ⁶³	110	35	32%	47	43%	28	25%
Kramer (2010) ⁸¹	349	113	32%	132	38%	104	30%
Lacasse (2009) ⁸	278	145	52%	126	45%	7	3%
Robertson (1946) ⁹⁷	57	31	54%	17	30%	9	16%
Total	1,342	543	40%	515	46%	184	14%

TABLE 5 Summary of Published Rates of Nausea and Vomiting in Late Pregnancy

First author (year)	Country	N	Number with NVP	Rate
Jahangiri (2011) ⁷⁵	USA	28	4	14.3%
Kramer (2010) ⁸¹	Canada	575	261	45.4%
Lindseth (2005) ⁸⁵	USA	108	35	32.4%
Meyer (1994) ⁹¹	UK	1,463	446	30.5%
Stewart (1988) ¹⁰⁰	England	135	32	23.7%
Stewart (1988) ¹⁰⁰	Scotland	107	9	8.4%
Wolkind (1978) ¹⁰⁸	UK	96	8	8.3%
		2,512	795	31.6%
		Meta-analytic average rate		23.5%
		Standard error		5.5%
		Minimum		8.3%
		Maximum		45.4%
		Median		23.7%

TABLE 6 Summary of reported rates of hyperemesis gravidarum

First author (year)	Country	Number with hyperemesis	Total number of women	Rate
Abraham (1994) ⁵³	Australia	2	100	2.0%
Adams (1994) ¹¹²	USA	27	1,825	1.5%
Askling (1999) ¹¹³	Sweden	8,186	1,027,213	0.8%
Bacak (2005) ¹¹⁴	USA	820	68,514	1.2%
Bailit (2005) ¹¹⁵	USA	2,466	520,739	0.5%
Bennett (1998) ¹¹⁶	USA	6,377	579,742	1.1%
Biggs (1975) ⁵⁶	Australia	2	116	1.7%
Cedergren (2008) ¹¹⁷	Sweden	7,938	781,725	1.0%
Chin (1989) ⁶¹	Hong Kong	5	1,453	0.3%
Fairweather (1968) ²	England	337	91,139	0.4%
Fell (2006) ¹¹⁸	Canada	1,301	157,922	0.8%
Fischer-Rasmussen (1990) ¹¹⁹	Sweden	30	6,700	0.4%
Fitzgerald (1956) ¹²⁰	Scotland	305	51,854	0.6%
Gadsby (1993) ⁷⁵	England	2	363	0.55%
Gazmararian (2002) ¹²¹	USA	337	46,179	0.7%
Hallak (1996) ¹²²	USA	138	12,473	1.1%
Jimenez (2000) ¹²³	Canada	254	19,839	1.3%
Källén (1987) ¹²⁴	Sweden	3,068	989,073	0.3%
Källén (2003) ⁸⁰	Sweden	39	3,675	1.1%
Klebanoff (1985) ⁸¹	USA	86	9,098	0.9%
Matsuo (2007) ¹²⁵	Japan	119	3,350	3.6%
Peckham (1929) ³	USA	43	6,491	0.7%
Reid (1938) ¹²⁶	USA	176	27,275	0.6%
Scott (1997) ¹²⁷	USA	24,998	833,264	3.0%
Semmens (1957) ¹⁰⁰	USA	33	2,500	1.3%
Tsang (1996) ¹²⁸	USA	193	13,053	1.5%
Vikanes (2008) ¹²⁹	Norway	8,383	900,074	0.9%
		65,665	6,155,941	1.1%
			Meta-analytic average	1.0%
			Standard error	0.1%
			Minimum	0.3%
			Maximum	3.6%
			Median	0.9%

REFERENCES

1. Weiss-Amer M. Medieval women's guides to food during pregnancy: origins, texts, and traditions. *Can Bull Med History* 1993;10:5-23.
2. Fairweather DV. Nausea and vomiting in pregnancy. *Am J Obstet Gynecol* 1968;102:135-75.

3. Peckham CH. Observations on 60 Cases of hyperemesis gravidarum. *Am J Obstet Gynecol* 1929;17:776-88.
4. Clark SM, Costantine MM, Hankins GD. Review of NVP and HG and early pharmacotherapeutic intervention. *Obstet Gynecol Int* 2012;252676. Epub 2011 Nov 24.
5. Munch S, Korst LM, Hernandez GD, Romero R, Goodwin TM. Health-related quality of life in women with nausea and vomiting of pregnancy: the importance of psychosocial context. *J Perinatol* 2011;31:10-20.
6. Chan OK, Sahota DS, Leung TY, Chan LW, Fung TY, Lau TK. Nausea and vomiting in health-related quality of life among Chinese pregnant women. *Aust N Z J Obstet Gynaecol* 2010;50:512-8.
7. Magee LA, Chandra K, Mazzotta P, Stewart D, Koren G, Guyatt GH. Development of a health-related quality of life instrument for nausea and vomiting of pregnancy. *Am J Obstet Gynecol* 2002;186(5 Suppl Understanding):S232-8.
8. Lacasse A, Rey E, Ferreira E, Morin C, Bérard A. Determinants of early medical management of nausea and vomiting of pregnancy. *Birth* 2009;36:70-7.
9. Attard CL, Kohli MA, Coleman S, Bradley C, Hux M, Atanackovic G, Torrance GW. The burden of illness of severe nausea and vomiting of pregnancy in the United States. *Am J Obstet Gynecol* 2002;186(5 Suppl Understanding):S220-7.
10. Piwko C, Ungar WJ, Einarson TR, Wolpin J, Koren G. The weekly cost of nausea and vomiting of pregnancy for women calling the Toronto Motherisk Program. *Curr Med Res Opin* 2007;23:833-40.
11. American Congress of Obstetricians and Gynecologists. ACOG Practice Bulletin number 52: nausea and vomiting of pregnancy. *Obstet Gynecol* 2004;103(4):803-13.
12. Gadsby R, Barnie-Adshead AM, Jagger C. Pregnancy nausea related to women's obstetric and personal histories. *Gynecol Obstet Invest* 1997;43:108-11.
13. Arsenault M-Y, Lane CA. SOGC clinical practice guideline. The management of nausea and vomiting of pregnancy. *J Obstet Gynaecol Can* 2002; 24: 817-23. Available at: <http://www.sogc.org/guidelines/public/120E-CPG-October2002.pdf>
14. Goodwin TM. Hyperemesis gravidarum. *Obstet Gynecol Clin North Am* 2008;35:401-17.
15. Philip B. Hyperemesis gravidarum: literature review. *Wis Med J* 2003;102(3):46-51.
16. Macle L, Varlet MN, Cathébras P. Hyperemesis gravidarum: a rare but potentially severe complication of the first trimester of pregnancy. *Rev Prat* 2010;60:759-64.
17. Nageotte MP, Briggs GG, Towers CV, Asrat T. Droperidol and diphenhydramine in the management of hyperemesis gravidarum. *Am J Obstet Gynecol* 1996;174:1801-6.
18. Trogstad LI, Stoltenberg C, Magnus P, Skjaerven R, Irgens LM. Recurrence risk in hyperemesis gravidarum. *BJOG* 2005;112(12):1641-5.
19. Einarson TR. Pharmacoeconomic applications of meta-analysis for single groups: antifungal onychomycosis lacquers as example. *Clin Ther* 1997;19:559-69.
20. Chou FH, Chen CH, Kuo SH, Tzeng YL. Experience of Taiwanese women living with nausea and vomiting during pregnancy. *J Midwifery Womens Health* 2006;51:370-5.
21. Chou FH, Kuo SH, Wang RH. A longitudinal study of nausea and vomiting, fatigue and perceived stress in, and social support for, pregnant women through the three trimesters. *Kaohsiung J Med Sci* 2008;24:306-14.
22. Emelianova S, Mazzotta P, Einarson A, Koren G. Prevalence and severity of nausea and vomiting of pregnancy and effect of vitamin supplementation. *Clin Invest Med* 1999;22:106-10.
23. Fejzo MS, Ingles SA, Wilson M, et al. High prevalence of severe nausea and vomiting of pregnancy and hyperemesis gravidarum among relatives of affected individuals. *Eur J Obstet Gynecol Reprod Biol* 2008;141:13-7.
24. Kuo SH, Wang RH, Tseng HC, Jian SY, Chou FH. A comparison of different severities of nausea and vomiting during pregnancy relative to stress, social support, and maternal adaptation. *J Midwifery Womens Health* 2007;52(1):e1-7.
25. Locock L, Alexander J, Rozmovits L. Women's responses to nausea and vomiting in pregnancy. *Midwifery* 2008;24:143-52.
26. Mazzotta P, Stewart D, Atanackovic G, Koren G, Magee LA. Psychosocial morbidity among women with nausea and vomiting of pregnancy: prevalence and association with anti-emetic therapy. *J Psychosom Obstet Gynaecol* 2000;21:129-36.
27. Corey LA, Berg K, Solaas MH, Nance WE. The epidemiology of pregnancy complications and outcome in a Norwegian twin population. *Obstet Gynecol* 1992;80:989-94.

28. Dickens G, Trethowan WH. Cravings and aversions during pregnancy. *J Psychosom Res* 1971;15:259-68.
29. Markl GE, Strunz-Lehner C, Egen-Lappe V, Lack N, Hasford J. The association of psychosocial factors with nausea and vomiting during pregnancy. *J Psychosom Obstet Gynaecol* 2008;29:17-22.
30. Markl GE, Strunz-Lehner C, Egen-Lappe V, Hasford J. Prescribing patterns of anti-emetic drugs during pregnancy in Germany. *Arch Gynecol Obstet* 2007;275:461-7.
31. Pepper GV, Craig Roberts S. Rates of nausea and vomiting in pregnancy and dietary characteristics across populations. *Proc Biol Sci* 2006;273(1601):2675-9.
32. Smith C, Crowther C, Beilby J, Dandeaux J. The impact of nausea and vomiting on women: a burden of early pregnancy. *Aust N Z J Obstet Gynaecol* 2000;40:397-401.
33. Tylden E. Hyperemesis and physiological vomiting. *J Psychosom Res* 1968;12:86-93.
34. Zhang J, Cai WW. Severe vomiting during pregnancy: antenatal correlates and fetal outcomes. *Epidemiology* 1991;2:454-7.
35. Chan RL, Olshan AF, Savitz DA, et al. Severity and duration of nausea and vomiting symptoms in pregnancy and spontaneous abortion. *Hum Reprod* 2010;25:2907-12.
36. Klebanoff MA, Mills JL. Is vomiting during pregnancy teratogenic? *Br Med J (Clin Res Ed)* 1986;292(6522):724-6.
37. Weigel MM, Weigel RM. The association of reproductive history, demographic factors, and alcohol and tobacco consumption with the risk of developing nausea and vomiting in early pregnancy. *Am J Epidemiol* 1988;127:562-70.
38. Flaxman SM, Sherman PW. Morning sickness: a mechanism for protecting mother and embryo. *Q Rev Biol* 2000;75:113-48.
39. Bashiri A, Neumann L, Maymon E, Katz M. Hyperemesis gravidarum: epidemiologic features, complications and outcome. *Eur J Obstet Gynecol Reprod Biol* 1995;63:135-8.
40. Borgeat A, Fathi M, Valiton A. Hyperemesis gravidarum: is serotonin implicated? *Am J Obstet Gynecol* 1997;176:476-7.
41. Depue RH, Bernstein L, Ross RK, Judd HL, Henderson BE. Hyperemesis gravidarum in relation to estradiol levels, pregnancy outcome, and other maternal factors: a seroepidemiologic study. *Am J Obstet Gynecol* 1987;156:1137-41.
42. Godsey RK, Newman RB. Hyperemesis gravidarum. A comparison of single and multiple admissions. *J Reprod Med* 1991;36:287-90.
43. Naef RW, Chauhan SP, Roach H, Roberts WE, Travis KH, Morrison JC. Treatment for hyperemesis gravidarum in the home: an alternative to hospitalization. *J Perinatol* 1995;15:289-92.
44. Jørgensen KT, Nielsen NM, Pedersen BV, Jacobsen S, Frisch M. Hyperemesis, gestational hypertensive disorders, pregnancy losses and risk of autoimmune diseases in a Danish population-based cohort. *J Autoimmun* 2012;38(2-3):J120-8.
45. Kuru O, Sen S, Akbayır O, Goksedef BP, Ozsürmeli M, Attar E, Saygılı H. Outcomes of pregnancies complicated by hyperemesis gravidarum. *Arch Gynecol Obstet* 2012;285:1517-21.
46. Safari HR, Alsulyman OM, Gherman RB, Goodwin TM. Experience with oral methylprednisolone in the treatment of refractory hyperemesis gravidarum. *Am J Obstet Gynecol* 1998;178:1054-8.
47. Saha S, Manlolo J, McGowan CE, Reinert S, Degli Esposti S. Gastroenterology consultations in pregnancy. *J Womens Health (Larchmt)* 2011;20:359-63.
48. Tan PC, Vani S, Lim BK, Omar SZ. Anxiety and depression in hyperemesis gravidarum: prevalence, risk factors and correlation with clinical severity. *Eur J Obstet Gynecol Reprod Biol* 2010;149:153-8.
49. Uguz F, Gezginc K, Kayhan F, Cicek E, Kantarci AH. Is hyperemesis gravidarum associated with mood, anxiety and personality disorders: a case-control study. *Gen Hosp Psychiatry* 2012;34:398-402.
50. van Stuijvenberg ME, Schabort I, Labadarios D, Nel JT. The nutritional status and treatment of patients with hyperemesis gravidarum. *Am J Obstet Gynecol* 1995;172:1585-91.
51. Franks AL, Kendrick JS, Olson DR, Atrash HK, Saftlas AF, Moien M. Hospitalization for pregnancy complications, United States, 1986 and 1987. *Am J Obstet Gynecol* 1992;166:1339-44.
52. Vilming B, Nesheim BI. Hyperemesis gravidarum in a contemporary population in Oslo. *Acta Obstet Gynecol Scand* 2000;79:640-3.
53. Abraham S, King W, Llewellyn-Jones D. Attitudes to body weight, weight gain and

- eating behavior in pregnancy. *J Psychosom Obstet Gynaecol* 1994;15:189-95.
54. Ananth CV, Rao PS. Epidemiology of nausea and vomiting of pregnancy and its relation to fetal outcome in a rural area. *J Trop Pediatr* 1993;39:313.
55. Biggs JS. Vomiting in pregnancy: Causes and management. *Drugs* 1975;9:299-306.
56. Boneva RS, Moore CA, Botto L, Wong LY, Erickson JD. Nausea during pregnancy and congenital heart defects: a population-based case control study. *Am J Epidemiol* 1999;149:717-25.
57. Brandes JM. First-trimester nausea and vomiting as related to outcome of pregnancy. *Obstet Gynecol* 1967;30:427-31.
58. Brown JE, Kahn ES, Hartman TJ. Profet, profits, and proof: do nausea and vomiting of early pregnancy protect women from "harmful" vegetables? *Am J Obstet Gynecol* 1997;176(1 Pt 1):179-81.
59. Chan RL, Olshan AF, Savitz DA, et al. Maternal influences on nausea and vomiting in early pregnancy. *Matern Child Health J* 2011;15:122-7.
60. Chin RK. Antenatal complications and perinatal outcome in patients with nausea and vomiting-complicated pregnancy. *Eur J Obstet Gynecol Reprod Biol* 1989;33:215-9.
61. Chou FH, Lin LL, Cooney AT, Walker LO, Riggs MW. Psychosocial factors related to nausea, vomiting, and fatigue in early pregnancy. *J Nurs Scholarsh* 2003;35:119-25.
62. Chou FH, Avant KC, Kuo SH, Fetzer SJ. Relationships between nausea and vomiting, perceived stress, social support, pregnancy planning, and psychosocial adaptation in a sample of mothers: a questionnaire survey. *Int J Nurs Stud* 2008;45:1185-91.
63. Crystal SR, Bowen DJ, Bernstein IL. Morning sickness and salt intake, food cravings and food aversion. *Physio Behav* 1999;67:181-7.
64. Davies TW, Williams DR, Whitaker RH. Risk factors for undescended testis. *Int J Epidemiol* 1986;15:197-201.
65. Diggory PI, Tomkinson JS. Nausea and vomiting in pregnancy. A trial of meclizine dihydrochloride with and without pyridoxine. *Lancet* 1962;2(7252):370-2.
66. DiIorio C. First trimester nausea in pregnant teenagers: incidence, characteristics, intervention. *Nurs Res* 1985;34:372-4.
67. Drake ML, Verhulst D, Fawcett J. Physical and psychological symptoms experienced by Canadian women and their husbands during pregnancy and the postpartum. *J Adv Nurs* 1988;13:436-40.
68. Evans AJ, Li TC, Selby C, Jeffcoate WJ. Morning sickness and thyroid function. *Br J Obstet Gynaecol* 1986;93:520-2.
69. Fairburn CG, Welch SL. The impact of pregnancy on eating habits and attitudes to shape and weight. *Int J Eating Disord* 1990;9:153-60.
70. Fairburn CG, Stein A, Jones R. Eating habits and eating disorders during pregnancy. *Psychosom Med* 1992;54:665-72.
71. Fawcett J, York R. Spouses' physical and psychological symptoms during pregnancy and the postpartum. *Nurs Res* 1986;35:144-8.
72. Fenster L, Eskenazi B, Windham GC, Swan SH. Caffeine consumption during pregnancy and spontaneous abortion. *Epidemiology* 1991;2:168-74.
73. Fitzgerald CM. Nausea and vomiting in pregnancy. *Br J Med Psychol* 1984;57:159-65.
74. Gadsby R, Barnie-Adshead AM, Jagger C. A prospective study of nausea and vomiting during pregnancy. *Br J Gen Pract* 1993;43:245-8.
75. Jahangiri F, Hirshfeld-Cytron J, Goldman K, Pavone ME, Gerber S, Klock SC. Correlation between depression, anxiety, and nausea and vomiting during pregnancy in an in vitro fertilization population: a pilot study. *J Psychosom Obstet Gynaecol* 2011;32:113-8.
76. Järnfelt-Samsioe A, Samsioe G, Velinder GM. Nausea and vomiting in pregnancy--a contribution to its epidemiology. *Gynecol Obstet Invest* 1983;16:221-9.
77. Järnfelt-Samsioe A, Eriksson B, Waldenström J, Samsioe G. Some new aspects on emesis gravidarum. Relations to clinical data, serum electrolytes, total protein and creatinine. *Gynecol Obstet Invest* 1985;19:174-86.
78. Jinadu MK, Daramola SM. Emotional changes in pregnancy and early puerperium among the Yoruba women of Nigeria. *Int J Soc Psychiatry* 1990;36:93-8.
79. Källén B, Lundberge G, Aberge A. Relationship between vitamin use, smoking and nausea and vomiting of pregnancy. *Acta Obstet Gynecol Scand* 2003;82:916-20.
80. Klebanoff MA, Koslowe PA, Kaslow R, Rhoads GG. Epidemiology of vomiting in early pregnancy. *Obstet Gynecol* 1985;66:612-6.
81. Kramer J. Nausea 1957;9:586-94.

82. Speert H, Guttmacher AF. Frequency and significance of bleeding in early pregnancy. *J Am Med Assoc* 1954;155:712-5.
83. Stewart J, Wheeler E, Scofield C. Regional differences in British attitudes to diet in pregnancy: priorities and pragmatism. *Ecol Food Nutr* 1988;20:211-29.
84. Tierson FD, Olsen CL, Hook EB. Nausea and vomiting of pregnancy and association with pregnancy outcome. *Am J Obstet Gynecol* 1986;155:1017-22.
85. Uddenberg N, Nilsson Å, Almgren PE. Nausea in pregnancy: psychological and psychosomatic aspects. *J Psychosomat Res* 1971;15:269-76.
86. Vellacott ID, Cooke EJ, James CE. Nausea and vomiting in early pregnancy. *Int J Gynaecol Obstet* 1988;27:57-62.
87. Walker AR, Walker BF, Jones J, Verardi M, Walker C. Nausea and vomiting and dietary cravings and aversions during pregnancy in South African women. *Br J Obstet Gynaecol* 1985;92:484-9.
88. Weigel MM, Weigel RM. Nausea and vomiting of early pregnancy and pregnancy outcome. An epidemiological study. *BJOG: Int J Obstet Gynaecol* 1989;96:1304-11.
89. Werler MM, Pober BR, Nelson K, Holmes LB. Reporting accuracy among mothers of malformed and nonmalformed infants. *Am J Epidemiol* 1989;129:415-21. and vomiting in pregnancy: prevalence and relationship with psychosocial determinants of health. Master of Nursing thesis, College of Nursing, University of Saskatchewan, Saskatoon, SK, 2010.
90. Kricker A, Elliott J, Forrest J, McCredie J. Congenital limb deficiency: maternal factors in pregnancy. *Aust N Z J Obstet Gynaecol* 1986;26:272-5.
91. Kullander S, Källén B. A prospective study of drugs and pregnancy. II. Anti-emetic drugs. *Acta Obstet Gynecol Scand* 1976;55:105-11.
92. Lacroix R, Eason E, Melzack R. Nausea and vomiting during pregnancy: A prospective study of its frequency, intensity, and patterns of change. *Am J Obstet Gynecol* 2000;182:931-7.
93. Lindseth G, Vari P. Nausea and vomiting in late pregnancy. *Health Care Women Int* 2005;26:372-86.
94. Little RE, Hook EB. Maternal alcohol and tobacco consumption and their association with nausea and vomiting during pregnancy. *Acta Obstet Gynecol Scand* 1979;58:15-7.
95. Louik C, Hernandez-Diaz S, Werler MM, Mitchell AA. Nausea and vomiting in pregnancy: maternal characteristics and risk factors. *Paediatr Perinat Epidemiol* 2006;20:270-8.
96. Masson GM, Anthony F, Chau E. Serum chorionic gonadotrophin (hCG), schwangerschaftsprotein 1 (SP1), progesterone and oestradiol levels in patients with nausea and vomiting in early pregnancy. *Br J Obstet Gynaecol* 1985;92:211-5.
97. McBride ML, Van den Steen N, Lamb CW, Gallagher RP. Maternal and gestational factors in cryptorchidism. *Int J Epidemiol* 1991;20:964-70.
98. Medalie JH. Relationship between nausea and/or vomiting in early pregnancy and abortion. *Lancet* 1957;273(6986):117-9.
99. Meyer LC, Peacock JL, Bland JM, Anderson HR. Symptoms and health problems in pregnancy: their association with social factors, smoking, alcohol, caffeine and attitude to pregnancy. *Paediatr Perinat Epidemiol* 1994;8:145-55.
100. Milkovich L, van den Berg BJ. An evaluation of the teratogenicity of certain antinauseant drugs. *Am J Obstet Gynecol* 1976;125:244-8.
101. Mori M, Amino N, Tamaki H, Miyai K, Tanizawa O. Morning sickness and thyroid function in normal pregnancy. *Obstet Gynecol* 1988;72(3 Pt 1):355-9.
102. O'Brien B, Zhou Q. Variables related to nausea and vomiting during pregnancy. *Birth* 1995;22:93-100.
103. Paarlberg KM, Vingerhoets AJ, Passchier J, Heinen AG, Dekker GA, van Geijn HP. Psychosocial factors as predictors of maternal well-being and pregnancy-related complaints. *J Psychosom Obstet Gynaecol* 1996;17:93-102.
104. Petitti DB. Nausea and pregnancy outcome. *Birth* 1986;13:223-6.
105. Robertson GG. Nausea and vomiting of pregnancy; a study in psychosomatic and social medicine. *Lancet* 1946;2(6419):336-41.
106. Semmens JP. Hyperemesis gravidarum evaluation and treatment. *Obstet Gynecol*
107. Whitehead SA, Andrews PLR, Chamberlain GVP. Characterisation of nausea and vomiting in early pregnancy: a survey of 1000 women. *J Obstet Gynaecol* 1992;12:364-9.
108. Wolkind S, Zajicek E. Psycho-social correlates of nausea and vomiting in pregnancy. *J Psychosom Res* 1978;22:1-5.
109. Yerushalmy J, Milkovich L. Evaluation of the teratogenic effect of meclizine in man. *Am J Obstet Gynecol* 1965;93:553-62.

110. Adams MM, Harlass FE, Sarno AP, Read JA, Rawlings JS. Antenatal hospitalization among enlisted servicewomen, 1987-1990. *Obstet Gynecol* 1994;84:35-9.
111. Askling J, Erlandsson G, Kaijser M, Akre O, Ekblom A. Sickness in pregnancy and sex of child. *Lancet* 1999;354(9195):2053.
112. Bacak SJ, Callaghan WM, Dietz PM, Crouse C. Pregnancy-associated hospitalizations in the United States, 1999-2000. *Am J Obstet Gynecol* 2005;192(2):592-7.
113. Bailit JL. Hyperemesis gravidarum: Epidemiologic findings from a large cohort. *Am J Obstet Gynecol* 2005;193(3 Pt 1):811-4.
114. Bennett TA, Kotelchuck M, Cox CE, Tucker MJ, Nadeau DA. Pregnancy-associated hospitalizations in the United States in 1991 and 1992: a comprehensive view of maternal morbidity. *Am J Obstet Gynecol* 1998;178:346-54.
115. Cedergren M, Brynhildsen J, Josefsson A, Sydsjö A, Sydsjö G. Hyperemesis gravidarum that requires hospitalization and the use of antiemetic drugs in relation to maternal body composition. *Am J Obstet Gynecol* 2008;198(4):412.e1-5.
116. Fell DB, Dodds L, Joseph KS, Allen VM, Butler B. Risk factors for hyperemesis gravidarum requiring hospital admission during pregnancy. *Obstet Gynecol* 2006 Feb;107(2 Pt 1):277-84.
117. Fischer-Rasmussen W, Kjaer SK, Dahl C, Asping U. Ginger treatment of hyperemesis gravidarum. *Eur J Obstet Gynecol Reprod Biol* 1990;38:19-24.
118. Fitzgerald JPB. Epidemiology of hyperemesis gravidarum. *Lancet* 1956; I (May 12):660-2.
119. Gazmararian JA, Petersen R, Jamieson DJ, Schild L, Adams MM, Deshpande AD, Franks AL. Hospitalizations during pregnancy among managed care enrollees. *Obstet Gynecol* 2002;100:94-100.
120. Hallak M, Tsalamandris K, Dombrowski MP, Isada NB, Pryde PG, Evans MI. Hyperemesis gravidarum. Effects on fetal outcome. *J Reprod Med* 1996;41:871-4.
121. Jimenez V, Marleau JD. Is hyperemesis gravidarum related to country of origin? Short report. *Can Fam Physician* 2000;46:1607-8.
122. Källén B. Hyperemesis during pregnancy and delivery outcome: a registry study. *Eur J Obstet Gynecol Reprod Biol* 1987;26:291-302.
123. Matsuo K, Ushioda N, Nagamatsu M, Kimura T. Hyperemesis gravidarum in Eastern Asian population. *Gynecol Obstet Invest* 2007;64:213-6.
124. Reid DE, Teel HM. The treatment of the vomiting of early pregnancy. *N Eng J Med* 1938;218:109-13.
125. Scott CL, Chavez GF, Atrash HK, Taylor DJ, Shah RS, Rowley D. Hospitalizations for severe complications of pregnancy, 1987-1992. *Obstet Gynecol* 1997;90:225-9.
126. Tsang IS, Katz VL, Wells SD. Maternal and fetal outcomes in hyperemesis gravidarum. *Internat. J Gynecol Obstet* 1996;55:231-5.
127. Vikanes A, Grijbovski AM, Vangen S, Magnus P. Variations in prevalence of hyperemesis gravidarum by country of birth: A study of 900,074 pregnancies in Norway 1967-2005. *Scand J Public Health* 2008;36:135-42.
128. Gadsby R, Barnie-Adshead AM. Nausea and vomiting of pregnancy: clinical information about nausea and vomiting of pregnancy and its relation to various aspects of women's personal and obstetric histories and other significant factors related to nausea and vomiting of pregnancy or hyperemesis gravidarum. A literature review. Available at: <http://www.pregnancysicknesssupport.org/documents/NVP-lit-review.pdf>
129. Koren G, Maltepe C. Pre-emptive therapy for severe nausea and vomiting of pregnancy and hyperemesis gravidarum. *J Obstet Gynaecol* 2004;24:530-3.
130. Koren G, Maltepe C. Preventing recurrence of severe morning sickness. *Can Fam Physician* 2006;52:1545-6.
131. Czeizel AE, Dudas I, Fritz G, Técsői A, Hanck A, Kunovits G. The effect of periconceptional multivitamin-mineral supplementation on vertigo, nausea and vomiting in the first trimester of pregnancy. *Arch Gynecol Obstet* 1992;251:181-5.
132. Koren G, Clark S, Hankins GD, et al. Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. *Am J Obstet Gynecol* 2010;203(6):571.e1-7.